Barclays PLC Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Barclays PLC increased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 117.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,300 shares of the biotechnology company’s stock after purchasing an additional 23,926 shares during the period. Barclays PLC owned approximately 0.15% of AnaptysBio worth $1,486,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ANAB. Frazier Life Sciences Management L.P. raised its holdings in shares of AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after purchasing an additional 1,265,891 shares during the last quarter. FMR LLC raised its holdings in shares of AnaptysBio by 15.3% during the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of AnaptysBio during the third quarter valued at approximately $8,874,000. Victory Capital Management Inc. raised its holdings in shares of AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

Analyst Ratings Changes

ANAB has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $40.00 target price (down from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Wells Fargo & Company cut their target price on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. HC Wainwright lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating and cut their target price for the company from $52.00 to $19.00 in a research report on Wednesday, December 11th. Finally, BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $41.45.

AnaptysBio Price Performance

ANAB opened at $14.21 on Monday. The firm has a market cap of $432.40 million, a P/E ratio of -2.34 and a beta of -0.02. AnaptysBio, Inc. has a 1-year low of $12.51 and a 1-year high of $41.31. The company has a 50 day simple moving average of $18.67 and a two-hundred day simple moving average of $28.19.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. Equities analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 65,184 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the purchase, the director now directly owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 33.70% of the stock is owned by company insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.